News

Huntsman Corporation Reports Q3 2024 Earnings Insights

Huntsman Corporation Reports Q3 2024 Earnings Insights

Huntsman Corporation Reports Q3 2024 Financial Results

Third Quarter Highlights

  • The net loss for the third quarter of 2024 was $33 million, contrasting with a net income of $0 million in the same period last year, resulting in a diluted loss per share of $0.19 compared to a diluted income per share of $0.00.
  • When adjusted, the net income attributable to Huntsman showed $17 million, down from the adjusted net income of $27 million from the previous year, with adjusted diluted income per share at $0.10 against $0.15 from last year.
  • Adjusted EBITDA for Q3 2024 was $131 million, slightly down from $136 million over the same period in 2023.
  • Net cash from continuing operations stood at $134 million, with free cash flow for Q3 2024 recorded at $93 million, down from $117 million in the prior year's quarter.
  • The company successfully issued $350 million in senior notes due in 2034 with a 5.7% coupon rate, utilizing the proceeds for general corporate purposes and debt repayments.

Operational Insights and Market Context

During the third quarter of 2024, Huntsman Corporation reported revenues of $1,540 million, highlighting the company's resilience amid fluctuating market conditions. CEO Peter R. Huntsman stated that the third quarter results align with expectations of stability within core construction and industrial markets. There was a notable 5% improvement in overall volumes compared to the previous year, despite ongoing challenges in margin stability.

Huntsman emphasized that construction and transportation collectively account for approximately 75% of the company's volume. He noted that while the short-term outlook remains subdued, particularly entering a seasonally lower fourth quarter, long-term prospects look positive with expected interest rate cuts from the Federal Reserve and ECB, along with anticipated stimulus measures in various regions.

Segment Performance Analysis

Polyurethanes Segment
Huntsman's Polyurethanes segment experienced revenue growth due to improved sales volumes, although lower average MDI selling prices slightly hampered overall performance. Demand recovery in certain markets contributed positively to production outputs.

Performance Products Segment
The Performance Products segment also saw revenue increases, primarily driven by enhanced demand in fuels and lubricants, as well as coatings and adhesives markets. Nonetheless, competitive pricing pressures tempered average selling prices, impacting segment profitability.

Advanced Materials Segment
Conversely, the Advanced Materials segment reported a decrease in revenues, largely attributed to reduced average selling prices against a backdrop of recovering demand in aerospace and coatings, which partially offset weaker industrial demand.

Financial Stability and Future Directions

In terms of liquidity, Huntsman Corporation recorded a strong cash position with approximately $1.7 billion in combined cash and borrowing capacity as of the end of Q3 2024. Explanations around the capital expenditures indicate planned investments ranging from $180 million to $190 million for the rest of the year, reflecting strategic growth initiatives.

Additionally, the company’s effective tax rate calculated at 115% emphasizes the challenges it faces within the tax landscape, with analysts projecting an adjusted effective tax rate to remain between 30% to 34% for the current year. This metric suggests a need for continuous monitoring of the tax implications on ongoing investments and operational strategies.

Outlook and Earnings Call Information

Huntsman has scheduled a conference call to detail its Q3 2024 results, slated for the upcoming Tuesday morning, providing a platform for shareholders and analysts to engage with management on the company’s performance and future expectations. This will allow stakeholders to gain deeper insights into Huntsman’s approach in navigating current market dynamics while capitalizing on future opportunities.

Frequently Asked Questions

What was Huntsman Corporation's net loss for Q3 2024?

The net loss attributable to Huntsman for Q3 2024 was $33 million.

How did Huntsman’s revenues change year-over-year?

Huntsman reported revenues of $1,540 million for Q3 2024, an increase from the $1,506 million reported in Q3 2023.

What is the outlook for Huntsman in the construction market?

The outlook remains moderate with some expected recovery supported by interest rate reductions and potential government stimulus measures.

What was the adjusted EBITDA for Huntsman in Q3 2024?

The adjusted EBITDA for Q3 2024 stood at $131 million, down from $136 million in the same quarter of 2023.

When is the earnings conference call for Huntsman scheduled?

The earnings conference call is scheduled for Tuesday at 10:00 a.m. ET.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lilly's Digital Healthcare Push with Hims & Hers

Updated Category News Views 194

Revolutionizing Access: Pharmaceuticals Meet Telehealth In an era where digital disruption is shaking every sector, Eli Lilly (NYSE:LLY) isn't sitting idle. They've just forged a partnership with Hims & Hers (NYSE:HIMS), one that's diving headfirst into the telehealth revolution. We're talking a slick merger of pharmaceuticals and digital platforms—offering FDA-approved...

Continue Reading
Delta Dental Expands Free Oral Care Access in NM

Updated Category News Views 160

Bridging Dental Care Gaps in New Mexico When the calendar flips to early November, Delta Dental of New Mexico is joining hands with the NM Mission of Mercy for a no-cost dental clinic at EXPO New Mexico. We're talking doors flying open at 5:15 a.m. sharp, on November 6 and 7. This isn’t some run-of-the-mill thing—they are targeting those who can't easily get or afford...

Continue Reading
Sass Magazine's 2026 COZY Issue Embraces Intentional Joy

Updated Category News Views 102

An Unexpected Shift in Sass's Seasonal Focus When you think November and December, it's easy to picture the hustle and bustle of holiday preparations—shopping, parties, running around. But toss all that hullabaloo out the window, because Sass Magazine has thrown a curveball for their 2026 release. They're steering the ship towards the calm, with their COZY Issue shaping...

Continue Reading
Lululemon Faces Class Action Amid Sales Decline

Updated Category News Views 136

Looks like Lululemon Athletica Inc. (NASDAQ: LULU) is in the hot seat, and not in the cozy yoga session kind of way. Investors are gearing up for a legal face-off thanks to a class action lawsuit alleging some serious corporate sleight of hand. What Triggered This Legal Storm? Turns out, between March 18 and September 3, 2026, things didn't go as planned for Lululemon....

Continue Reading
Tenax Sued: Investors Face Class Action Over TNX-103

Updated Category News Views 83

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Continue Reading
TCL CSOT's OLED Move In Marks Next Phase of Growth

Updated Category News Views 96

A Landmark Moment in OLED Manufacturing Alright, let me drop a quick line here. TCL CSOT just shifted gears with their t8 production line in Guangzhou. It’s not your typical assembly line story—this one's all about pulling the future into the present. We're talking the world's first 8.6-generation Inkjet Printing OLED production line, for crying out loud. They've just...

Continue Reading
Datavault AI's Turbulent Boardroom Saga Escalates

Updated Category News Views 104

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 117

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
New Frontiers in Glaucoma Care: Less Drops Required?

Updated Category News Views 77

Eyeing New Glaucoma Treatment Strategies You think glaucoma treatment is all about popping eye drops day in and day out? Well, turns out, things are shifting down in Racine, Wisconsin. Folks at HelloNation have been spilling the beans on earlier glaucoma interventions that might just lighten your load of daily medications. Doctors I. Paul Singh and R. Krishna Sanka...

Continue Reading
MNTN Revenue Miss Sparks Shareholder Investigation

Updated Category News Views 79

When Revenue Goes South, Shares Follow Nothing like a Friday morning stock bloodbath to shake things up. MNTN, Inc. (NYSE:MNTN) had traders tossing back extra caffeine shots on November 5, 2026, when the company reported third-quarter revenues of $80.3 million. Let's just say that number didn't quite sit well with the folks who'd been banking on an $87.7 million...

Continue Reading

Top 5 Most Recently Viewed Articles

Perpetua Resources Corp. Class Action Lawsuit and Investor Alert

Updated Category News Views 167

Understanding the Class Action Lawsuit Against Perpetua Resources Corp. Investors in Perpetua Resources Corp. (NASDAQ: PPTA) should take note of recent developments regarding a class action securities lawsuit aimed at recovering losses incurred due to alleged securities fraud. This legal action encompasses claims made during a specific period, potentially affecting a...

Continue Reading
Telix Pharmaceuticals Hits Record Revenue and Expands Guidance

Updated Category News Views 390

Telix Pharmaceuticals Reports Record Revenues in Q3 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has unveiled an impressive financial performance for the third quarter of 2025, showcasing unaudited group revenues of approximately $206 million. This figure marks a substantial year-over-year increase of 53%, revealing the company's significant growth...

Continue Reading
Bio-Techne Showcases Breakthrough Solutions at Neuroscience 2024

Updated Category News Views 208

Bio-Techne's Commitment to Neuroscience Research Bio-Techne Corporation (NASDAQ: TECH) is preparing for an exciting presentation at the Society for Neuroscience's annual meeting, Neuroscience 2024. Scheduled for October 5-9 in Chicago, this prestigious event will feature Bio-Techne as they share advancements that are setting new standards in neuroscience research....

Continue Reading
Important Update for Lineage, Inc. Investors on Class Action

Updated Category News Views 214

Class Action Suit Opportunities for Lineage, Inc. Investors The Rosen Law Firm, known for advocating investor rights, is calling attention to an essential opportunity for those who purchased common stock of Lineage, Inc. (NASDAQ: LINE). Investors should be aware of the impending lead plaintiff deadline of September 30, 2025. Why Join the Lawsuit? If you bought shares of...

Continue Reading
AST SpaceMobile Prepares for BlueBird 6 Launch and Future Growth

Updated Category News Views 129

AST SpaceMobile Gears Up for BlueBird 6 Launch AST SpaceMobile is set to launch its advanced satellite, BlueBird 6, marking a significant milestone for the company. This launch is crucial for boosting the firm’s space-based cellular broadband network and is being closely watched by investors eager to understand the company’s expansion into full-scale operations. Key...

Continue Reading